Literature DB >> 16942794

Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer.

P O Van Trappen1, T Cullup, R Troke, D Swann, J H Shepherd, I J Jacobs, S A Gayther, C A Mein.   

Abstract

OBJECTIVE: To date, most mtDNA mutations in cancer have been identified in the control region (D-loop) containing the major promoters. However, almost all studies used one sample per tumor and there is no clear evidence whether metastatic deposits harbor different mtDNA variants. To establish whether different mtDNA variants can be found in the same cancer but at different sites, we analyzed a series of unilateral and bilateral primary epithelial ovarian cancers as well as paired metastatic tumor deposits.
METHODS: We sequenced the D-loop region in 52 different tumor samples of 35 ovarian cancer cases, as well as matched normal tissues. Seventeen of those 35 cases had bilateral ovarian cancer, with a sample from each tumor analyzed.
RESULTS: Eighty-six polymorphisms (4 new in ovarian cancer) were detected, and 9 different somatic mtDNA mutations were found in 26% (9 of 35) of ovarian cancer cases; all were homoplasmic in nature. Six of the mutations were novel in ovarian cancer. In 24% (4 of 17) of cases with bilateral ovarian tumors, different mtDNA variants were found between paired tumors, suggesting the presence of different clonal populations of cancer cells. Metastatic tumor deposits showed identical mtDNA variants to those found in at least one of the ovarian tumors in cases with bilateral ovarian cancer.
CONCLUSION: Our data demonstrate that multiple tumor samples from the same patient may harbor different mtDNA variants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942794     DOI: 10.1016/j.ygyno.2006.07.010

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  No mitochondrial DNA deletions but more D-loop point mutations in repeated pregnancy loss.

Authors:  Seyed Mohammad Seyedhassani; Massoud Houshmand; Seyed Mehdi Kalantar; Glayol Modabber; Abbas Aflatoonian
Journal:  J Assist Reprod Genet       Date:  2010-05-25       Impact factor: 3.412

2.  Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Authors:  Charles Li; Elena Bonazzoli; Stefania Bellone; Jungmin Choi; Weilai Dong; Gulden Menderes; Gary Altwerger; Chanhee Han; Aranzazu Manzano; Anna Bianchi; Francesca Pettinella; Paola Manara; Salvatore Lopez; Ghanshyam Yadav; Francesco Riccio; Luca Zammataro; Burak Zeybek; Yang Yang-Hartwich; Natalia Buza; Pei Hui; Serena Wong; Antonella Ravaggi; Eliana Bignotti; Chiara Romani; Paola Todeschini; Laura Zanotti; Valentina Zizioli; Franco Odicino; Sergio Pecorelli; Laura Ardighieri; Dan-Arin Silasi; Babak Litkouhi; Elena Ratner; Masoud Azodi; Gloria S Huang; Peter E Schwartz; Richard P Lifton; Joseph Schlessinger; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-24       Impact factor: 11.205

Review 3.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome.

Authors:  Cody C Cook; Masahiro Higuchi
Journal:  Biochim Biophys Acta       Date:  2011-09-02

Review 4.  Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer.

Authors:  Thomas C Beadnell; Adam D Scheid; Carolyn J Vivian; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

5.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis.

Authors:  Jianxin Lu; Lokendra Kumar Sharma; Yidong Bai
Journal:  Cell Res       Date:  2009-07       Impact factor: 25.617

7.  Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.

Authors:  Jessica M Hearn; Isolda Romero-Canelón; Alison F Munro; Ying Fu; Ana M Pizarro; Mathew J Garnett; Ultan McDermott; Neil O Carragher; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-10       Impact factor: 11.205

Review 8.  The mitochondrial landscape of ovarian cancer: emerging insights.

Authors:  Pallavi Shukla; Keshav K Singh
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

9.  Mitochondrial Copy Number and D-Loop Variants in Pompe Patients.

Authors:  Fatemeh Bahreini; Massoud Houshmand; Mohammad Hossein Modaresi; Hassan Tonekaboni; Shahriar Nafissi; Ferdoss Nazari; Seyed Mohammad Akrami
Journal:  Cell J       Date:  2016-08-24       Impact factor: 2.479

Review 10.  Mitochondrial DNA instability and metabolic shift in human cancers.

Authors:  Hsin-Chen Lee; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2009-02-23       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.